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Introduction: Amorphous and co-amorphous (CAM) materials have been used in the last years 
as a strategy to overcome the low bioavailability of the majority (90%) of drugs due to low water 
solubility and low dissolution rates from solid dosage forms (1,2). Unit operations used to 
produce oral solid dosage forms impose stress conditions (e.g. pressure during tableting) on 
amorphous systems and can promote the recrystallization of the amorphous drug (3). This work 
presents new usages of spectroscopic based analytical methods and computational models to 
quantify the fraction of amorphous olanzapine (OLZ) in a formulation intended to produce 
immediate release OLZ tablets. 
Materials and Methods: Near infrared (NIR) and Fourier-transform infrared (FTIR) 
spectroscopies were used to quantify the fraction of co-amorphous OLZ (30%) with saccharin 
(SAC; 18%) in formulations containing also calcium phosphate (27%), microcrystalline cellulose 
(20%) and povidone (5%). Tablets (250mg) were obtained using a universal testing machine fit 
with circular punches (7.5mm Ø), at a constant compression rate of 10mm/min (n=5). Different 
compression forces (8 and 25kN) and dwell times (DT; 0 and 20 min) were considered for the 
production of tablets. Evaluation of the impact of the compression conditions on the 
recrystallization of OLZ from a co-amorphous system was based on a computational model. 
Results: Using a 2nd derivative filter to process both NIR and FTIR spectra, the quantification of 
amorphous olanzapine was possible with a root mean square error of calibration and prediction 
above 2% (Fig. 1). The method was further applied to evaluate the stability of co-amorphous 
systems after tableting, revealing that no significant recrystallization occurred, i.e. the co-
amorphous were stable under the stress conditions applied.  
 
 
Figure 1- NIR calibration curve used to predict 
the amorphous fraction of OLZ. 
 
 
 
 
 
 
 
 
 
 
Table 1- Predicted fraction of amorphous OLZ by NIR and FTIR 
spectroscopy, in tablets prepared with the co-amorphous system. 
 
Discussion and Conclusions: Using both NIR and FTIR spectroscopy it was possible to 
develop a methodology to monitor and quantify the conversion of the amorphous OLZ present 
in blends as a co-amorphous of OLZ:SAC. The models developed have also demonstrated that 
all tablets obtained were stable, since no recrystallization was observed.  
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ID NIR FTIR 
CAM Physical Mixture 100 100 
CAM 8kN 0DT 89 98 
CAM 8kN 20DT 94 94 
CAM 25kN 0DT 95 93 
CAM 25kN 20DT 98 95 
